Abstract| Volume 20, ISSUE 5, SUPPLEMENT , S61, May 2018

Characterization of a pathogen reduced human platelet lysate

      As more manufactured cellular therapies move into clinical use, there is an increasing call for cell culture media supplements that are of high quality, compatible with different cell types, and not supply limited. Human platelet lysate (HPL) is one of several supplements available for manufacturing cell products. Derived from multiple platelet units, HPL contains the same types of growth factors and cytokines in FBS and human AB serum at comparative levels. Despite the low risk with platelet units screened and tested using the same criteria as transfusable blood, transmission of infectious agents, notably viruses, remains a consideration for human platelet-derived products such as HPL. Pooling platelet concentrates can improve HPL consistency and performance, but increases the statistical risk of viral contamination.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect